FRANCE — Glooko and Sanofi have collaborated to integrate the SoloSmart device into the Glooko platform, providing support for healthcare professionals and individuals with diabetes worldwide.
The SoloSmart device is an add-on for the SoloStar and DoubleStar insulin injection pens that captures data regarding insulin dose, date, and time of injection, which can be visualized in the Glooko app.
This integration will enable SoloStar and DoubleStar users to track insulin dose and timing through the Glooko app, allowing for visualization of the relationship between insulin dose and blood glucose levels.
The Glooko app will also integrate other features such as exercise metrics, food tracking, weight, and blood pressure, creating actionable insights for personalized care.
Glooko CEO Russ Johannesson highlighted the importance of the partnership, stating that it will expand their global reach and provide best-in-class technologies to benefit people with diabetes.
The integrated product will be offered in English and local languages and gradually launched across several countries later this year.
Sanofi Digital Healthcare global head Jared Josleyn stated that the collaboration aims to improve daily management for individuals living with diabetes.
According to a news release, Sanofi aims to utilize Glooko’s global footprint spanning over 8,000 clinics. It seeks to increase the accessibility of digital solutions in each country where it makes SoloSmart available.
SoloSmart currently remains unapproved for marketing in the U.S. However, the add-on device currently has CE-mark approval and will gradually roll out in several countries later this year, with an option to expand the launch beyond the initial geographic scope.
Glooko has raised US$30 million in a Series D funding round and has partnered with other pharmaceutical companies such as Novo Nordisk and Eli Lilly.
The emergence of advanced technologies has brought about a new era of diabetes management with the development of automated insulin delivery (AID) systems.
These systems, which utilize data and algorithms, can help to improve blood glucose control and reduce the risk of hypoglycemia, potentially minimizing long-term health complications.
While AID is still in its early stages, the idea of creating a fully functioning artificial pancreas through the combination of devices and data is becoming a reality.
Additionally, data-driven approaches to healthcare are facilitating the growth of an ecosystem of interconnected digital solutions that can help people with diabetes to manage their health more effectively.
Recent developments in pharmaceuticals are also encouraging, with two new classes of medicines, SGLT-2 inhibitors, and GLP-1 agonists, having a significant impact on glucose management and reducing the risk of cardiovascular disease and weight gain.
There have also been promising developments in the prevention and reversal of type 2 diabetes through digital therapeutics.
However, it is important to note that there is still a significant lag in diabetes management in low-resourced areas of the globe.
To address this, there is a need for innovation and collaboration to bring these technologies and treatments to those who need them.
With the number of adults with diabetes projected to rise significantly in the coming years, addressing diabetes will be a critical challenge for healthcare systems globally.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
Be the first to leave a comment